Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | SLC1A3 | P43003 | 4/20 | 0.41 |
| ▸ | SLC1A2 | P43004 | 4/20 | 0.41 |
| ▸ | SLC1A1 | P43005 | 4/20 | 0.41 |
| ▸ | CTSK | P43235 | 6/20 | 0.38 |
| ▸ | CTSL | P07711 | 4/20 | 0.35 |
| ▸ | CTSB | P07858 | 4/20 | 0.35 |
| ▸ | CTSH | P09668 | 3/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18072127 | 0.86 | LMNA (0.47) | LMNASLC1A3SLC1A2SLC1A1CTSK | |
| SCHEMBL6894933 | 0.83 | EPHX1 (0.38) | CTSKCTSLCTSBCTSH | |
| SCHEMBL6894215 | 0.83 | LMNA (0.42) | LMNASLC1A3SLC1A2SLC1A1CTSK | |
| SCHEMBL18069591 | 0.83 | LMNA (0.45) | LMNASLC1A3SLC1A2SLC1A1CTSK | |
| SCHEMBL26296842 | 0.80 | LMNA (0.49) | LMNASLC1A3SLC1A2SLC1A1CTSK | |
| SCHEMBL4630436 | 0.80 | LMNA (0.52) | LMNASLC1A3SLC1A2SLC1A1CTSK | |
| SCHEMBL698391 | 0.80 | LMNA (0.52) | LMNASLC1A3SLC1A2SLC1A1CTSK | |
| SCHEMBL1669840 | 0.79 | LMNA (0.59) | LMNASLC1A3SLC1A2SLC1A1 | |
| SCHEMBL698000 | 0.77 | LMNA (0.48) | LMNASLC1A3SLC1A2SLC1A1CTSK | |
| SCHEMBL9180286 | 0.77 | SLC1A3 (0.40) | LMNASLC1A3SLC1A2SLC1A1CTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6677331-B2 | HAVING SUBSTITUTED IMIDAZO(5,1-B)THIAZOLE GROUP AT 2-POSITION; MICROBIOCIDES AGAINST BETA-LACTAMASE PRODUCING BACTERIA AND RESISTANT PSEUDOMONAS | MEIJI SEIKA KAISHA, LTD. (JP) | 2004-01-13 | — | — | US | disclosed |
| US-20030149016-A1 | Novel carbapenem derivatives | KANO YUKO (JP) | 2003-08-07 | — | — | US | disclosed |
| US-6458780-B1 | IMIDAZO(5,1-B)THIAZOLE GROUP AT THE 2-POSITION ON THE CARBAPENEM RING HAVE HIGH ANTI-MICROBIAL ACTIVITIES AGAINST .BETA.-LACTAMASE PRODUCING BACTERIA, MRSA, RESISTANT-PSEUDOMONAS AERUGINOSA, PRSP, ENTEROCOCCI, AND | MEIJI SEIKA KAISHA, LTD. (JP) | 2002-10-01 | — | — | US | disclosed |
| EP-1022279-B1 | NEW CARBAPENEM DERIVATIVES | MEIJI SEIKA KAISHA (JP) | 2002-09-04 | — | — | EP | disclosed |
| US-6310056-B1 | 2-SUBSTITUTED WITH A IMIDAZO(5,1-B)THIAZOLE GROUP; TREATING INFECTIONS, INCLUDING ANTIBIOTIC RESISTANT BACTERIAL INFECTIONS | MEIJI SEIKA KAISHA, LTD. (JP) | 2001-10-30 | — | — | US | disclosed |
| EP-1101766-A1 | NOVEL CARBAPENEM DERIVATIVES | MEIJI SEIKA KAISHA LTD. (JP) | 2001-05-23 | — | — | EP | disclosed |
| EP-1022279-A1 | NEW CARBAPENEM DERIVATIVES | MEIJI SEIKA KAISHA LTD. (JP) | 2000-07-26 | — | — | EP | disclosed |
| EP-0337637-B1 | 2-(Heterocyclylthio)carbapenem derivatives their preparation and their use as antibiotics | SANKYO CO (JP) | 1994-11-30 | — | — | EP | disclosed |
| EP-0597821-A1 | 2-(Heterocyclylthio)carbapenem derivatives their preparation and their use as antibiotics | Sankyo Company Limited (JP) | 1994-05-18 | — | — | EP | disclosed |
| US-5242914-A | 2-(heterocyclylthio) carbapenem derivatives, their preparation and their use as antibiotics | SANKYO COMPANY, LIMITED (JP) | 1993-09-07 | — | — | US | disclosed |
| US-5104867-A | 2-(HETEROCYCLYLTHIO)CARBAPENEM DERIVATIVES, THEIR PREPARATION AND THEIR USE AS ANTIBIOTICS | SANKYO COMPANY, LIMITED (JP) | 1992-04-14 | — | — | US | disclosed |
| EP-0337637-A1 | 2-(Heterocyclylthio)carbapenem derivatives their preparation and their use as antibiotics | Sankyo Company Limited (JP) | 1989-10-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030149016-A1 | Novel carbapenem derivatives | DPEP1, TMPRSS15, STK35 | LMNA 2043/4885SLC1A3 3952/4885SLC1A2 4591/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.